On Friday, Chesapeake Energy Corporation (NYSE:CHK)’s shares inclined 9.02% to $7.86.
Chesapeake Energy Corporation (CHK) declared that it is notifying holders of its 2.75% Contingent Convertible Senior Notes due 2035 that they have the option, following the terms of the Notes, to require Chesapeake to purchase on November 15, 2015 (the “Repurchase Date”) all or a portion of such holders’ Notes (the “Repurchase Option”). The repurchase price is equal to 100% of the aggregate principal amount of the Note, together with accrued but unpaid interest thereon, up to but not counting the Repurchase Date (the “Repurchase Price”), offered that interest payable on November 15, 2015 will be paid to the holders in whose names the Notes are registered at the close of business on November 1, 2015, the record date preceding to the Repurchase Date. Payment of the Repurchase Price will be made on November 16, 2015, which is the next succeeding business day following the Repurchase Date. If all outstanding Notes are surrendered for repurchase, the aggregate cash repurchase price will be about $396.0 million. Chesapeake intends to fund the Repurchase Price using accessible cash.
The Repurchase Option commences recently and expires at 5:00 p.m., New York time, on November 15, 2015. Holders may exercise the Repurchase Option by delivering a repurchase notice to The Bank of New York Mellon, the paying agent, before 5:00 p.m., New York time, on November 10, 2015. Holders may withdraw their election to exercise their Repurchase Option at any time preceding to 5:00 p.m., New York time, on November 13, 2015, which is the business day right away preceding the Repurchase Date. In order to exercise the Repurchase Option, or withdraw Notes formerly surrendered, a holder must follow the additional procedures set forth in the notice that is being sent to all registered holders of the Notes.
Chesapeake Energy Corporation produces oil and natural gas through acquisition, exploration, and development of from underground reservoirs in the United States. It holds interests in natural gas resource plays, counting the Haynesville/Bossier Shales in northwestern Louisiana and East Texas; the Marcellus Shale in the northern Appalachian Basin of West Virginia and Pennsylvania; and the Barnett Shale in the Fort Worth Basin of north-central Texas.
Bristol-Myers Squibb Co (NYSE:BMY)’s shares gained 3.58% to $62.20.
Bristol-Myers Squibb Company (BMY) declared that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.Recent declaration marks the first and only FDA approval of a Regimen of two Immuno-Oncology agents in cancer. This indication is approved under accelerated approval based on tumor response rate and durability of response.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials
The approval is based on data from the pivotal study, CheckMate -069, which was the first to report outcomes of the Opdivo + Yervoy Regimen in formerly untreated patients with unresectable or metastatic melanoma. Results from the trial demonstrated a statistically noteworthy(p<0.001) enhance in confirmed objective response rate – the study’s primary endpoint – in patients with BRAF wild-type melanoma treated with the Opdivo + Yervoy Regimen [60% (95% CI: 48-71; p<0.001)] contrast to those treated with Yervoy monotherapy [11% (95% CI: 3-25)]. Complete responses were seen in 17% of patients. Partial responses were seen in 43% of the Regimen group and 11% of the Yervoy monotherapy group. The Opdivo + Yervoy Regimen demonstrated a 60% reduction in the risk of progression vs. Yervoy alone (HR=0.40; 95% CI: 0.22-0.71; p<0.002). Median PFS was 8.9 months with the Regimen (95% CI: 7.0, NA) and 4.7 months with Yervoy alone (95% CI: 2.8-5.3).1 This trial provides clinical rationale for targeting the immune system with two Immuno-Oncology agents in metastatic melanoma.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
At the end of Friday’s trade, Twitter Inc (NYSE:TWTR)‘s shares surged 6.65% to $26.32.
All “New To The Street” videos continue to be aired through its video marketing beta program with Twitter (NYSE:TWTR). “New To The Street” is excited to declare its current line-up for the taping of their newest T.V. series, set for October 22, 2015 at their state of the art studios in New York City, New York.
For the first time, Mr. Daniel de Liege, CEO of Alliance Media Group Holdings, Inc. (OTCQB: ALLM), will be on the show, talking about this Florida based public holding company which focuses on the advancement of renewable energy, emerging fuel and energy technologies.
Additionally, first timer Mark Bradley, CEO of The Players Network (OTC PINK: PNTV), will be on the show talking about the company’s medical marijuana industry operations, their media platform called “NextGen” and their business affiliation with The ArcView Group. Mr. Bradley will provide dialogue, highlighting his mission to create shareholder value by identifying and monetizing opportunities in emerging niche markets. PNTV anticipates growing shareholder value through its long term and aggressive stance in its two main industries, marijuana and media, arguably the fastest growth industries in the US recently.
Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. It offers various products and services for users, counting Twitter that allows users to create, distribute, and discover content; and Vine and video, a mobile application that enables users to create and distribute short looping videos.
Boston Scientific Corporation (NYSE:BSX), ended its Friday’s trading session with 1.38% gain, and closed at $16.92.
Boston Scientific Corporation (BSX) webcasted its conference call talk about financial results and business highlights for the third quarter ended September 30, 2015 on Wednesday, October 28, 2015 at 8 a.m. ET.
The call will be hosted by Mike Mahoney, president and chief executive officer, and Dan Brennan, executive vice president and chief financial officer.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
DISCLAIMER:
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.